Axsome Therapeutics Proudly Supports Migraine and Headache Awareness Month Alongside the Association of Migraine Disorders

Company Overview - Axsome Therapeutics, Inc. is a biopharmaceutical company focused on treating central nervous system (CNS) disorders, with a mission to address significant gaps in care and improve patient outcomes through innovative products [3] - The company has an industry-leading neuroscience portfolio that includes FDA-approved treatments for major depressive disorder, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, along with multiple late-stage development programs targeting serious neurological and psychiatric conditions affecting over 150 million people in the U.S. [3] Industry Context - Migraine affects approximately 40 million people in the U.S. and is the second leading cause of disability worldwide, highlighting the critical need for effective treatment options [2] - The Association of Migraine Disorders emphasizes the importance of funding and advancing migraine research, as well as educating patients and healthcare providers about the condition [2] Community Engagement - In recognition of Migraine and Headache Awareness Month, Axsome is supporting various Miles for Migraine Run, Walk or Relax events across the U.S. and providing resources for patients and their families affected by migraine [1][3] - The company collaborates with leading migraine advocacy organizations to share educational resources and support for individuals impacted by migraine [3][5]